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We have previously demonstrated that continuous infusion of low molecular weight (LMW) heparin delays autoantibody
production and development of lupus nephritis in (NZBxNZW)F1 (B/W) mice. In this study we investigated the effect of LMW
heparin on renal cytokine and chemokine expression and on nucleosome-mediated activation of nucleosome-specific splenocytes.
Total mRNA extracted from kidneys of heparin-treated or -untreated B/W mice was analysed by qPCR for the expression of
several cytokines, chemokines, and Toll-like receptors. Splenocytes taken from B/Wmice were stimulated with nucleosomes with
or without the presence of heparin. Splenocyte cell proliferation as thymidine incorporation and the expression of costimulatory
molecules and cell activation markers were measured. Heparin treatment of B/W mice reduced the in vivo expression of CCR2,
IL1𝛽, and TLR7 compared to untreated B/W mice. Nucleosome-induced cell proliferation of splenocytes was not influenced by
heparin. The expression of CD80, CD86, CD69, CD25, CTLA-4, and TLR 2, 7, 8, and 9 was upregulated upon stimulation by
nucleosomes, irrespective of whether heparin was added to the cell culture or not. In conclusion, treatment with heparin lowers
the kidney expression of proinflammatory mediators in B/W mice but does not affect nucleosomal activation of splenocytes.
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
syndrome characterized by inflammation and damage in
several organs [1]. Lupus nephritis is one of the most severe
manifestations of SLE, and autoantibodies against nuclear
components such as dsDNA and nucleosomes are central
in the development of the organ disease. These autoanti-
bodies are found together with chromatin in electron dense
structures (EDS) located in the mesangial matrix (MM) and
glomerular basement membranes (GBM) of nephritic kid-
neys, as demonstrated in both murine [2–4] and human [5]
forms of lupus nephritis. Several studies have demonstrated
that the main autoantigen in lupus nephritis, assumingly
serving as both inducer and target for the immune system,
indeed is chromatin fragments or nucleosomes [6–9].
Studies have shown that SLE patients and lupus prone
mice are assumed to suffer from impaired clearance of
apoptotic debris [10, 11]. This may result in an increased
load of extracellular chromatin and formation of immune
complexes (ICs) [12–14]. Deposition of ICs within the MM
and GBM is associated with renal expression of proinflam-
matory chemokines attracting leukocytes in SLE patients
and murine models of lupus-like nephritis [15–17]. This will
lead to increased influx of Fc receptor bearing effector cells
activated by circulating ICs, which together will increase the
ongoing inflammation and tissue destruction [18]. Interfering
with activation of intrinsic kidney cells and effector cells may
prevent or lower the expression of cytokines and chemokines.
We have previously demonstrated that lupus prone
(NZBxNZW)F1 (B/W) mice receiving low molecular weight
(LMW) heparin showed delayed anti-dsDNA antibody pro-
duction compared to sham-treated control mice [19]. In vitro
studies also showed that LMW heparin inhibited chromatin
binding to components of GBM, and heparin increased
enzymatic degradation of chromatin, as demonstrated using
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Dnase1 and proteinase K enzymes [19]. The aim of this study
was to investigate if LMW heparin treatment, by preventing
binding of ICs to the GBM, had an effect on cytokine,
chemokine and Toll-like receptor mRNA expression profiles
during the development of lupus nephritis and if heparin
could prevent nucleosomal activation of splenocytes.
2. Materials and Methods
2.1. Ethics Statement. The treatment and care of animals were
conducted in accordance with the Norwegian Animal Exper-
imental and Scientific Purposes Act of 1986. All experimental
protocols were approved by the Norwegian Animal Research
Authority (NARA).
2.2. Mice and Grouping of Mice. Female B/W and BALB/c
mice were purchased from Jackson Laboratory (Bar Harbor,
Maine,USA).TheB/Wmicewere divided into 4 groups based
on age, deposition of IgG in glomeruli, anti-dsDNA ab titers
in sera taken at end point, proteinuria, and heparin treatment.
Group 1 (4–10w.o, 𝑛 = 17) had no depositions of IgG
within the kidneys and no detectable levels of anti-dsDNA
antibodies in sera. Deposition of IgG was observed within
the kidney of Group 2 (mesangial nephritis determined
by mesangial deposits, 18–30w.o, 𝑛 = 15) and Group 3
(end-stage organ disease determined by GBM deposits and
proteinuria, 23–36w.o, proteinuric, 𝑛 = 18) B/W mice with
detectable levels of anti-dsDNA ab in sera. In the heparin-
treated group (Group 4, 𝑛 = 5) 1/5 mice were anti-dsDNA
antibody negative, and 2/5 mice developed proteinuria [19].
Age-matched BALB/c mice was used as controls.
2.3. Isolation of Kidneys from B/W Mice. B/W mice at age 4
weeks old (w.o) until the development of severe proteinuria
(23–40w.o) and age-matched control BALB/Cmicewere sac-
rificed in groups of 3 as described previously [4].Theheparin-
treated mice included five mice given a daily subcutaneous
dose of 50𝜇g of Klexane (LMW heparin, Aventis Pharma
AS) by osmotic pumps (Scanbur, Oslo, Norway) from the
age of 12 weeks [19]. The osmotic pumps were primed and
filled according to the manufacturer’s instruction, implanted
subcutaneously in the upper dorsal region, and replaced
every ∼30 days. Control mice received saline by saline-
filled osmotic pumps. The heparin-treated mice were paired
randomly with saline-treated control mice. The pairs of BW
mice were sacrificed when the control mice developed full-
blown lupus nephritis (31–39w.o). The kidneys were isolated
and processed for RNA isolation, immunohistochemistry
(IHC) analysis, and immune electron microscopy (IEM)
analysis, as described in [4].
2.4. Determination of Proteinuria and of Anti-dsDNA Anti-
bodies by ELISA. Full-blown lupus nephritis was defined
when proteinuria reached 4+, as determined by urine stix
(Bayer Diagnostics, Bridgend, UK): 0-1+ (<1 g protein/
liter urine) was regarded as physiological proteinuria; 2+
(≥1 g/liter to <3 g/liter) was regarded as mild proteinuria, and
3+ (≥3 g/liter to <20 g/liter) and 4+ (≥20 g/liter) was regarded
as heavy proteinuria. Sera were collected and stored at −20∘C
until use. Serum antibodies against dsDNA were detected by
ELISA as described in [20, 21]. Serawere diluted twofold from
1/100 to 1/6400 in PBS (0.02% Tween), and the 163c3 anti-
dsDNA mAb (provided by T. N Marion, Memphis, TN, USA
[22]) was included in each ELISA for assay validation and
determination of cut-off value.
2.5. Immunohistochemistry. Detection of autoantibodies
bound in glomeruli was performed on Zink-fixed kidneys
embedded in paraffin. Four 𝜇m sections of the kidney
samples were dewaxed with xylene, rehydrated in graded





endogenous peroxidase. Sections were further blocked with
10% goat serum and 1% BSA in PBS before incubation with
anti-mouse IgG antibodies conjugated with horseradish
peroxidase (Sigma-Aldrich, St. Louis, MO, USA) diluted
1 : 100 in blocking solution. Washed sections were then
incubated with chromogen DAB (Dako, Glostrup, Denmark)
for detection of primary antibody. IHC using Polink-2 Plus
HRP detection kits for tissue (Golden Bridge International,
Inc, Mukilteo, WA, USA) was performed on frozen kidney
sections. Antibodies against mice CCR2 and TLR7 were
purchased from Abcam (Cambridge, UK), and IL1𝛽 was
obtained from R&D systems (Minneapolis, USA).
2.6. Isolation of Splenocytes from B/W Mice. Spleens were
collected and mashed through a 100𝜇m cell strainer
with DMEM-10 (4.5 g/L glucose, 10% fetal bovine serum,
10000U/mL penicillin, and 10mg/mL streptomycin and L-
glutamine) (Invitrogen, Carlsbad, CA, USA). Erythrocytes





, and 0.1mM Na
2
EDTA adjusted to pH 7.2–7.4), and
splenocytes were washed and resuspended in DMEM-10.
2.7. Proliferation Assay. Splenocytes, at 105 cells/200𝜇L/well,
were seeded out in a 96-well round bottom plate. The cells
were incubated with different stimulators (all in triplicates):
nucleosomes (10 𝜇g/mL) prepared from the murine BALB/c
3T3 clone A31 fibroblast cell line (ATCC CCL-163) and
characterized as previously described in [23], nucleosomes
(10 𝜇g/mL) together with LMW heparin (Enoxaparin, Klex-
ane, Aventis Pharma AS, Oslo, Norway, 24𝜇g/mL) at a molar
ratio of 1 : 100 (nucleosomes (determined as core nucleo-
some equivalents): heparin), LMWheparin (24𝜇g/mL), con-
canavalin A (con A) (2.5 𝜇g/mL) (Sigma-Aldrich), and conA
with LMW heparin (1 : 200) and HMGB1 (1 𝜇g/mL) (Sigma-
Aldrich). Tritiated thymidine (1𝜇Ci/well) (Perkin Elmer,
MA, USA) was added to the cell cultures 16 hours before
harvesting at 20 h, 4 days, and 7 days. Cells were transferred to
filter paper, each spot representing one well was isolated, and
threemL of scintillation fluid (Ultima goldXR, Perkin Elmer)
was added to each piece of filter paper. Counts per minute
(cpm) were measured using a liquid scintillation analyzer
(1900 TR, Packard Instruments). A proliferative response was
defined as a stimulation index (SI) calculated as the mean
cpmvalue for stimulated cells in triplicates dividedwithmean
cpmvalue formedium stimulated cells at the same time point.
Positive proliferation was regarded if SI was greater than 2,
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provided that the cpm of antigen-stimulated cells was above
100 cpm.
2.8. Western Blot. Western blot was performed with SDS-
NuPage-gels and blotting system according to the manu-
facturer (Invitrogen). Rabbit anti-mouse HMGB1 antibody
(Sigma-Aldrich) was used for detection of HMGB1. Recom-
binant HMGB1 protein (Sigma-Aldrich) was used as control
(31 kDa on SDS-PAGE).
2.9. RNA Isolation. Differently stimulated splenocytes (all
in triplicate) were harvested for total RNA isolation at
the same time points as for the proliferation assay. Cells
were collected and washed in ice cold PBS before isolating
RNA with Trizol reagent (200𝜇L) (Invitrogen) according
to the manufacturer’s protocol with minor modification.
Chloroform (40𝜇L) was used for phase separation, and
RNA was precipitated with 96% ethanol containing 0.3M
NaAc and 20 𝜇g/mL glycogen. RNA was washed in 80%
ethanol and dried before dissolving in Rnase-free water. The
concentration and quality of extracted RNAwere determined
spectrophotometrically using NanoDrop (NanoDrop tech-
nologies, Wilmington, USA).
2.10. Gene Expression Analysis. Preparation of cDNA and
quantitative PCR (qPCR) was performed exactly as described
in [24]. The following TaqMan gene expression assays were
used: Mm00446973 m1 for TBP as housekeeping gene,
Mm01183378 m1 for CD69, Mm01340213 m1 for CD25,
Mm00434256 m1 for IL2, Mm00515420 m1 for CD19,
Mm00486849 m1 for CTLA-4, Mm01157262 m1 for TLR8,
Mm00711659 m1 for CD80, Mm00444543 m1 for CD86,
Mm00446590 m1 for TLR7, Mm00446193 m1 TLR9,
Mm01210732 g1 for IL6, Mm00433859 m1 for CXCL1 (KC),
Mm99999062 m1 for IL10, Mm99999061 mH for IL1𝛽,
Mm01168134 m1 for IFN-𝛾, Mm00443258 m1 for TNF𝛼,
Mn00441242 m1 for CCL2, Mn00438270 m1 for CCR2,
Mn01308393 g1 for CCL7, Mn00444228 m1 for CCL20,
Mn00436450 m1 for CXCL2, Mn00436451 g1 for CXCL5,
and Mn00442346 m1 for TLR2. TaqMan Fast Universal
PCR master mix (2X) and gene expression assays were all
obtained from Applied Biosystems. Medium stimulated cells
at each time point (20 hours, 4 days, and 7 days) served as
reference, and changes in gene expression were calculated
with the ΔΔCT method shown as fold change.
2.11. Measurements of Cytokines in Cell Supernatants. Cytok-
ine analyses were performed with ELISAMAX Standard Sets
for mouse IL10 (BioLegend, San Diego, CA, USA) or mouse
TNF𝛼 ELISA kit (Thermo scientific, Rockford, IL, USA).
All assays were performed according to the manufacturer’s
instructions.
2.12. Statistical Analysis. Unpaired 𝑡-test was used to compare
mean of two sets of measurements. Statistical comparisons
of groups were made by one-way ANOVA followed by Bon-
ferroni posttest. Statistical comparisons of treatment were
analyzed using two-way ANOVA followed by Bonferroni
posttest. All tests were performed using GraphPad Prism
version 5.0.
3. Results
3.1. The Effect of LMW Heparin on In Vivo mRNA Expression
Levels of Cytokines, Chemokines, Chemokine Receptor, and
TLRs. To measure the effect of LMW heparin treatment on
cytokine and chemokine expression individual TaqMan real
time PCR assays (qPCR) on a selection of cytokine and
chemokine genes were performed. The mRNA expression
levels of CCL2, CCL7, CCL20, CXCL1, and CXCL2 were
significantly upregulated in Group 3 B/W mice compared to
Group 1 mice and were, although somewhat reduced, not
significantly different in the heparin-treated mice (Figures
1(a)–1(f)). There were no significant increase of CCL2, CCL7,
and CXCL1mRNA expressions in age-matched BALB/c mice
(Figures 1(f)–1(h)). CCR2, IL1𝛽, IL10, TLR2, TLR7, TLR8,
and TLR9 mRNA expressions were significantly increased
in Group 3 mice (Figures 2(a)–2(g), resp.), and CCR2, IL1𝛽
and TLR7 mRNA expression levels were significantly lower
in heparin-treated mice (Group 4) compared to nephritic
mice (Group 3) (Figures 2(a), 2(b), and 2(e), resp.). Anal-
ysis of CCR2, IL1𝛽, and TLR7 protein expression within
the tissue verified these reduced gene expression levels
observed in heparin-treated mice compared to untreated
mice (Figure 3(a)). CCR2 expression was observed in tubu-
lar and glomerular areas of nephritic mice, whereas the
expression in heparin-treated mice were confined to tubuli
(Figure 3(a)). IL1𝛽 was observed in infiltrating cells that
were reduced in heparin-treated mice (Figure 3(a)). TLR7
expression was observed on infiltrating cells, tubuli and
glomeruli of untreated nephritic mice, and a reduced expres-
sion that was mainly observed in glomeruli and between
tubuli of heparin-treated mice (Figure 3(a)). A Spearman
correlation analysis (Table 1) on all parameters performed
on age-matched pairs of nontreated and heparin-treated
B/W mice demonstrated an inverse correlation of heparin
treatment and the development of proteinuria and the gene
expression of CCR2, IL1𝛽, and IL10. The duration of anti-
dsDNA antibody production (in weeks) correlated positively
with the development of proteinuria and with expression of
CCL2, CCR2, CCL20, TLR2, TLR7, CXCL1, and IL0 (Table 1).
Anti-dsDNA ab production and successive deposition of
immune complexes within the kidney during the disease
increase the gene expression of cytokine and chemokines,
while heparin treatment lowers the expression.
3.2. Splenocytes from Nephritic Mice Are Activated by Nucle-
osomes in Absence or Presence of Heparin. To analyse the
effect of LMW heparin on cell proliferation, gene expression
of cell activation markers, and proinflammatory cytokines,
splenocytes isolated from prenephritic and nephritic B/W
mice were stimulated with nucleosomes, either in absence
or presence of heparin. Nucleosomes used in the present
experiments contained HMGB1 (Figures 3(b) and 3(c)).
The size of nucleosomes ranged from mononucleosomes
to polynucleosomes (Figure 3(d)). The splenocytes from
prenephritic mice did not respond to nucleosomes in any
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Figure 1: LMW heparin treatment does not affect chemokine mRNA expression within the kidneys of B/W mice. The mRNA expression of
CCL2 (a), CCL7 (b), CCL20 (c), CXCL1 (d), and CXCL2 (e) was significantly increased in Group 3 mice and were not significantly reduced
in heparin-treated mice.The mRNA expression of CCL2 (f), CCL7 (g), and CXCL1 (h) was also analyzed in age-matched BALB/c mice. Data
is given as Log 2 of mean ± SEM of fold change values normalized against 4-week-old mice (𝑛 = 3). 𝑃 values are calculated using one-way
ANOVA followed by Bonferroni posttest. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001. Group 1: 4–10w.o B/Wmice (𝑛 = 17); Group 2: 18–30w.o B/W
mice with mesangial IC deposits without proteinuria (𝑛 = 15); Group 3: 23–36w.o B/W mice with proteinuria (𝑛 = 18); Group 4: 31–39w.o
heparin-treated B/Wmice (𝑛 = 5).
of the experiments (data not shown). However, stimulation
of cells from prenephritic mice with conA resulted in a
stimulation index similar to those obtained from nephritic
mice with no significant reduction by heparin (Figures 3(e)
and 3(f), resp.). The spontaneous proliferation in medium
measured as cpm revealed that nephritic mice had a sig-
nificantly higher proliferation at 20 hours which persisted
over time compared to splenocytes from prenephritic mice
(Figure 3(g)). Splenocytes fromnephriticmice proliferated in
response to nucleosomes, but the presence of LMW heparin
did not affect this response (Figure 4). In three of the five
mice, we observed a nucleosome-induced proliferation, while
the kinetics differed between the mice (Figures 4(a)–4(c)).
The presence of LMW heparin did not have any influence
on the proliferation of splenocytes taken from these mice
(Figures 4(a)–4(c)). Splenocytes from two nephritic mice did
apparently not respond to nucleosomes (Figures 4(d) and
4(e)). Splenocytes from these mice demonstrated high initial
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Figure 2: Heparin treatment affects themRNA expression of CCR2, IL1𝛽, and TLR7 in kidneys of B/Wmice.ThemRNA expression of CCR2
(a), IL1𝛽 (b), IL10 (c), TLR2 (d), and TLR7 (e) was increased in Group 3 mice compared to Group 1 mice.ThemRNA expression of CCR2 (a),
IL1𝛽 (b), and TLR7 (e) was significantly reduced in Heparin-treated mice compared to Group 3 mice. Data is given as Log 2 of mean ± SEM
of fold change values normalized against 4-week-old mice (𝑛 = 3). 𝑃 values are calculated using one-way ANOVA followed by Bonferroni
posttest. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
levels of tritiated thymidine incorporation already at 20 h,
indicating that they either were in a phase of proliferation
when seeded into the wells, or they were fast responders
giving responses before 20 h (Figures 4(d) and 4(e), (insets)
and 4(f)). Stimulationwith isolatedHMGB1 or LMWheparin
did not give a significant proliferative response in cells from
any mouse tested.
Nucleosome-stimulated splenocytes from nephritic B/W
mice, analysed by qPCR, showed transcriptional upregula-
tion of genes encoding cell activation markers for antigen
presenting cells: CD80, CD86 (Figures 5(a) and 5(b)), acti-
vated T cells: CD69, CTLA4, and IL2 (Figures 5(c)–5(e)),
and the B cell marker CD19 (Figure 5(f)). The presence
of LMW heparin in the cultures did not influence the
increased transcription of these markers in response to
stimulation with nucleosomes (Figures 5(a)–5(f)). Responses
to nucleosome stimulation with or without heparin also
included an increased transcription of the genes encoding the
cytokines IL1𝛽, IL6, IL10, IFN-𝛾, TNF𝛼, the receptors TLR2,
TLR7, TLR8, TLR9, and the chemokine CXCL1 (mouse IL8
analogue) (Table 2).
4. Discussion
Recent results have demonstrated that B/Wmice treated with
LMW heparin presented a significantly delayed and reduced
6 Clinical and Developmental Immunology


















































































Figure 3: Characterization of nucleosomes used in this study and spontaneous splenocyte proliferation. Immunohistochemistry analysis
detecting CCR2, IL1𝛽, and TLR7 protein expression in kidneys of 31 w.o heparin or untreated B/Wmice (a). SDS PAGE of nucleosomes and
HMGB1 used in cell culture stimulations ((b), lane 1: MW standard, lane 2: nucleosomes (3 𝜇gmeasured as DNA), and lane 3: HMGB1 (1𝜇g)).
Western blot showing HMGB1 (arrows) in nucleosomes purified from A31 cell line ((c), lane 1: MW standard, lane 2: HMGB1 (0.1 𝜇g), and
lane 3: nucleosomes (2𝜇g measured as DNA)). Agarose gel electrophoresis of nucleosomes showing a distribution of nucleosome sizes ((d),
lane 1: MW standard, lane 2: nucleosomes (3 𝜇g measured as DNA)). Stimulation index (SI) of cells from prenephritic mice (e) and nephritic
mice (f) stimulated with conA with or without heparin. Splenocytes from nephritic mice have a significantly higher proliferation (counts
per minute, CPM) at 20 hours which persisted over time compared to splenocytes from prenephritic mice (g). Mean values and SD were
calculated from triplicates from each cell culture. ∗Statistically significant (𝑃 < 0.05) compared to medium stimulated cells at the same time
point. Scale = 100 𝜇m.
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Table 1: Spearman correlation matrix performed on gene expression in heparin and nontreated age-matched B/Wmice.
Age Hep. w. ab. Pos. Prot. CCL2 CCR2 CCL7 CCL20 CXCL1 CXCL2 TLR2 TLR7 IL1𝛽 IL10
Age 0,000 0,363 0,463 0,517 0,369 0,591 0,640 0,714 0,739 0,443 0,394 0,271 0,074
Heparin 1,000 −0,601 −0,655 −0,453 −0,731 −0,383 −0,522 −0,313 −0,244 −0,453 −0,592 −0,870 −0,801
Weeks antibody
positive 0,303 0,066 0,694 0,677 0,874 0,603 0,812 0,652 0,572 0,739 0,855 0,622 0,745
Proteinuria 0,178 0,040 0,026 0,798 0,798 0,798 0,798 0,798 0,798 0,722 0,722 0,798 0,722
CCL2 0,126 0,189 0,032 0,006 0,745 0,964 0,830 0,600 0,636 0,903 0,806 0,661 0,624
CCR2 0,294 0,016 0,001 0,006 0,013 0,648 0,891 0,527 0,515 0,782 0,879 0,830 0,915
CCL7 0,072 0,275 0,065 0,006 <0,001 0,043 0,818 0,661 0,721 0,794 0,721 0,552 0,515
CCL20 0,046 0,122 0,004 0,006 0,003 0,001 0,004 0,685 0,733 0,830 0,915 0,697 0,770
CXCL1 0,020 0,378 0,041 0,006 0,067 0,117 0,038 0,029 0,964 0,576 0,576 0,479 0,333
CXCL2 0,015 0,497 0,084 0,006 0,048 0,128 0,019 0,016 <0,001 0,588 0,588 0,442 0,333
TLR2 0,200 0,189 0,015 0,018 0,000 0,008 0,006 0,003 0,082 0,074 0,927 0,733 0,721
TLR7 0,260 0,071 0,002 0,018 0,005 0,001 0,019 <0,001 0,082 0,074 <0,001 0,758 0,855
IL1𝛽 0,449 0,001 0,055 0,006 0,038 0,003 0,098 0,025 0,162 0,200 0,016 0,011 0,855
IL10 0,839 0,005 0,013 0,018 0,054 <0,001 0,128 0,009 0,347 0,347 0,019 0,002 0,002
Table 2: Transcriptional levels of cytokines and Toll-like receptors in stimulated splenocytes.
Relative gene expression levelsa in splenocytes from nephritic mice
Genes Nucleosomes Nucleosome lmw heparin
20 hours 4 days 7 days 20 hours 4 days 7 days
IL1𝛽 15.87 ± 5.09 77.78 ± 7.92∗ 72.69 ± 29.08∗ 15.54 ± 4.62 86.84 ± 13.09∗ 80.86 ± 10.80∗
IL6 1.80 ± 0.42 6.91 ± 2.46 35.25 ± 8.08∗ 1.52 ± 0.57 6.57 ± 1.21 37.25 ± 15.09∗
IL10 1.29 ± 0.53 1.90 ± 0.25 3.55 ± 0.12∗ 1.47 ± 0.48 1.79 ± 0.21 4.45 ± 2.16∗
IFN-𝛾 2, 35 ± 0.79 4, 10 ± 2.62 10,99 ± 0.38∗ 3, 00 ± 1.18 6, 53 ± 4.57 11,20 ± 4.03∗
TNF𝛼 4.75 ± 0.32∗ 5.45 ± 0.82∗ 1.97 ± 0.34∗ 5.44 ± 1.23∗ 8.37 ± 1.24∗ 2.04 ± 0.14∗
CXCL1 110.70 ± 47.16∗ 51.80 ± 11.37 81.63 ± 46.31∗ 91.75 ± 27.24∗ 45.92 ± 4.40 91.75 ± 23.38∗
TLR2 1.81 ± 0.75b 10.94 ± 0.65∗ 19.70 ± 4.40∗ 1.69 ± 0.48 10.15 ± 1.39∗ 19.02 ± 2.08∗
TLR7 2.09 ± 0.82∗ 3.21 ± 0.57∗ 2.30 ± 0.38∗ 1.47 ± 0.41 2.04 ± 0.12∗ 2.23 ± 1.10∗
TLR8 0.34 ± 0.12∗ 1.64 ± 0.19∗ 3.31 ± 0.09∗ 0.43 ± 0.23 1.77 ± 0.31∗ 2.61 ± 0.28∗
TLR9 1.11 ± 0.23 2.01 ± 0.05 4.08 ± 0.87∗ 1.98 ± 1.05 2.76 ± 0.36∗ 5.10 ± 1.79∗
aData is given as fold change compared to medium stimulated splenocytes at the same time point. ∗Statistically significant (𝑃 < 0.05) change in mRNA levels
compared to medium stimulated cells. bMean values and SD were calculated from triplicates.
anti-DNA antibody response in vivo. We also observed a
significantly delayed development of lupus nephritis in the
heparin-treated mice [19]. These results may theoretically be
due to at least 2 different effects of LMW heparin. Heparin
makes nucleosomesmore sensitive to enzymatic degradation,
and particularly to Dnase1 [19] similar to what has been
described by, for example, Villeponteau [25]. This effect
resulted in a nearby complete degradation of nucleosomal
DNA in vitro [19]. LMW heparin also inhibited binding of
nucleosomes to components of GBM, like laminins and col-
lagen IV, possibly due to altered net charge and conformation
of the nucleosomal structure induced by heparin [19]. These
phenomenons have also been observed by van Bruggen et al.
[26], although they provided a different explanation for
reduced nucleosome binding to membranes.
When analysing cytokine and chemokine mRNA expres-
sion levels in the kidneys of treated and untreated mice, we
demonstrated significantly reduced levels of CCR2, IL1𝛽, and
TLR7 in heparin-treated mice. CCR2 is mainly expressed by
tubular cells in the murine kidney in addition to effector cells
like macrophages. Reduced expression of CCR2 may either
be because of less influx of macrophages or less expression
by tubular cells. Here we also demonstrate an increased
expression of CCR2 within the glomeruli of sick mice. The
reduced mRNA levels of IL1𝛽 and TLR7 may indicate lower
degree of influx of immune cells normally expressing them.
Heparin has been shown to have an effect on adhesion
molecules and cytokines, and can bind to chemokines [27]. In
addition heparin can inhibit complement activation [28, 29].
Classical activation of the complement system also provides
chemotaxis of granulocytes and macrophages through the
split products of C3a-C5a [30]. LMW heparin has been
shown to have an inhibitory effect on mesangial cell prolifer-
ation, signal transduction, and reduce apoptosis upon several






































































































Figure 4: Splenocyte cell proliferation in response to nucleosomes. Splenocytes derived from three of the nephritic mice showed increased
proliferation in response to nucleosomes; LMW heparin did not interfere with proliferation magnitude or kinetics ((a), (b), and (c),
proliferation is shown as stimulation index (SI)). Apparently no proliferation was seen in cell cultures from two of the nephritic mice ((d),
(e)), although responses in cpm indicate that the cells proliferate ((d), (e), inserted figures). Proliferations in medium for individual mice are
shown as cpm (f). Mean values and SD were calculated from triplicates. ∗Statistically significant (𝑃 < 0.05) compared to medium stimulated
cells at the same time point.
activation stimuli [31–33]. The effect of LMW heparin on
activation ofmesangial cells by nucleosome and nucleosome-
containing immune complexes remains to be determined.
The ability of heparin to prevent binding of nucleosomes
to membranes could theoretically also indicate that heparin
could preclude binding and uptake of nucleosomes by APCs
as well as binding of T-cell receptors to nucleosome-derived
peptide-MHC class II complexes. This would eventually
provide an explanation to the observed reduced autoimmune
anti-dsDNA antibody response beyond pure degradation
and loss of immunogenic nucleosomes [19]. In the present
study, all nephritic mice produced antibodies to DNA, and
splenocytes from3 of them responded readily to nucleosomes
in vitro. The reason why splenocytes from two of the five
nephriticmice did not proliferate in response to nucleosomes
is unclear but may be due to the fact that they seemed to be
activated in vivo at the time theywere cultured and unrespon-
sive to further stimuli the next 7 days.This was demonstrated
by high cpm values in medium-stimulated cultures already at
the early phase of the cultures, and no increase in cpm was
observed thereafter during the 7 days observation time. In
cultures of splenocytes from Group 3 mice, T-cell activation
markers together with upregulation of activation markers for
APCs and B cells were observed. This was also accompanied
by cytokine production reflecting a true innate immune
response against nucleosomes. The cell proliferation in these
cell cultures was the same when nucleosomes were presented
in the presence of LMW heparin.
In the nucleosome-stimulated splenocyte cultures de-
rived from nephritic mice, we also observed an increase in
TLR mRNA expression levels in response to nucleosomes.
TLR 7 and 8 are activated by ssRNA and g-rich oligonu-
cleotides [34, 35], while TLR 9 is activated by CpG motifs
on DNA usually found on bacterial DNA [36]. They exert
important roles in induction of autoimmunity [37–39].
These receptors are located in intracellular compartments
of APCs, and activation of them leads to upregulation of
co-stimulatory molecules and cytokine secretion needed for









































































































































































































































































































































Figure 5:ThemRNA levels of leukocyte activationmarkers in nucleosome- and nucleosome/heparin-stimulated splenocytes from a nephritic
mouse. The mRNA levels of CD80 (a), CD86 (b), CD69 (c), CTLA-4 (d), CD25 (e), and CD19 (f) are all upregulated over time in response
to stimuli with nucleosomes and nucleosomes/heparin. Expression levels for each gene, measured by qPCR, were normalized against the
expression level of TBP. Data are given as Log 2 of mean ± SEM of fold change values normalized against medium stimulated cells and are
representative for at least three independent analyses. Fold change is shown as mean of triplicates ± SD. ∗Statistically significant (𝑃 < 0.05)
change in mRNA levels compared to medium stimulated cells at the same time point.
activation of T cells [40]. The upregulation of TLR 7, 8, and
9 seen in nucleosome-stimulated splenocytes indicates that
nucleosomes activate APCs through interaction with these
TLRs or that they activate cytokine production that will lead
to their upregulation [41, 42]. Another TLR that has been
implicated in inducing autoimmunity against nucleosomes
is TLR2 which binds nuleosome-HMGB1 complexes [43].
This binding will result in activation of APCs with increased
expression of costimulatorymolecules required for activation
of T cells [44]. The nucleosomes used in these experiments
contained HMGB1 which explains the upregulation of TLR2
transcription [45]. Heparin can bind HMGB1 [46] which
may dislocate HMGB1 from the nucleosomes and interfere
with the binding and uptake by APCs through the TLR2
pathway. In our studies, we did not observe any difference
when LMW heparin was added to the cultures. Stimulation
with pure HMGB1 did not result in proliferative responses
in splenocytes in agreement with previously reported results
[43].
In this study we did not observe any inhibitory effects of
LMW heparin on nucleosome-mediated activation of APCs
or on proliferation of nucleosome specific T cells taken from
the spleen. This indicates that even if LMW heparins bind
nucleosomes andmay change their net charge and conforma-
tion [19, 25, 47], it does not affect the uptake and presentation
of nucleosomes to nucleosome specific T cells frommice with
full-blown lupus nephritis.Thus, a more relevant explanation
for the reduced anti-dsDNA antibody response in heparin-
treated B/W mice would therefore be increased by enzyme-
mediated elimination of the nucleosome as a central antigen
[19]. Reduced load of nucleosomal antigens will lead to
diminished activation of APCs, T cells, and B cells and will
10 Clinical and Developmental Immunology
consequently lead to reduced amount of autoantibodies. In
context of the in vitro experimental results described in the
present study, the concentration of nucleases and proteases
available in the cell cultures may be too low to affect the
elimination of nucleosomes, in contrast to the concentrations
observed in sera [48]. In line with this, the reduced in
vivo mRNA levels of CCR2, IL1𝛽, and TLR7 indicate that
reduced levels of nucleosomal antigensmight lead to reduced
activation of intrinsic cells and less influx of effector cells.
5. Conclusion
One of the beneficial effects of LMW heparin in vivo in B/W
mice, demonstrating delayed development of autoimmunity
to nucleosomes and lupus nephritis [19], relies on its ability
to lower the inflammatory processes of immune complex
deposition.
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